Paredes R - Search Results

1

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.

Trinité B, Pradenas E, Marfil S, Rovirosa C, Urrea V, Tarrés-Freixas F, Ortiz R, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Lepore R, Izquierdo-Useros N, Trujillo G, Trapé J, González-Fernández C, Flor A, Pérez-Vidal R, Toledo R, Chamorro A, Paredes R, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Blanco J. Trinité B, et al. Among authors: paredes r. Viruses. 2021 Jun 12;13(6):1135. doi: 10.3390/v13061135. Viruses. 2021. PMID: 34204754 Free PMC article.

2

The potential role of interleukin-2 in patients with HIV infection.

Paredes R, López Benaldo de Quirós JC, Fernández-Cruz E, Clotet B, Lane HC. Paredes R, et al. AIDS Rev. 2002 Jan-Mar;4(1):36-40. AIDS Rev. 2002. PMID: 11998783 Review.

3

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, Díaz M, Marfil S, Negredo E, García-Prado J, Tural C, Sirera G, Clotet B. Ruiz L, et al. Among authors: paredes r. J Infect Dis. 2003 Oct 1;188(7):977-85. doi: 10.1086/378411. Epub 2003 Sep 23. J Infect Dis. 2003. PMID: 14513417 Clinical Trial.

4

New antiretroviral drugs and approaches to HIV treatment.

Paredes R, Clotet B. Paredes R, et al. AIDS. 2003;17 Suppl 4:S85-96. doi: 10.1097/00002030-200317004-00010. AIDS. 2003. PMID: 15080184 Review. No abstract available.

5

[Duration of antiretroviral combinations].

Paredes R, Clotet B. Paredes R, et al. Med Clin (Barc). 2004 May 15;122(18):696-7. doi: 10.1016/s0025-7753(04)74359-6. Med Clin (Barc). 2004. PMID: 15171830 Spanish. No abstract available.

6

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.

Negredo E, Bonjoch A, Paredes R, Puig J, Clotet B. Negredo E, et al. Among authors: paredes r. Clin Infect Dis. 2005 Sep 15;41(6):901-5. doi: 10.1086/432879. Epub 2005 Aug 15. Clin Infect Dis. 2005. PMID: 16107993 Clinical Trial.

7

Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Dalmau J, Puertas MC, Azuara M, Mariño A, Frahm N, Mothe B, Izquierdo-Useros N, Buzón MJ, Paredes R, Matas L, Allen TM, Brander C, Rodrigo C, Clotet B, Martinez-Picado J. Dalmau J, et al. Among authors: paredes r. Clin Infect Dis. 2009 Jan 15;48(2):229-38. doi: 10.1086/595704. Clin Infect Dis. 2009. PMID: 19093810 Free PMC article.

8

Clinical approach to drug resistance interpretation: expert advice.

Clotet B, Paredes R. Clotet B, et al. Among authors: paredes r. Curr Opin HIV AIDS. 2007 Mar;2(2):145-9. doi: 10.1097/COH.0b013e32801470f6. Curr Opin HIV AIDS. 2007. PMID: 19372880

9

Clinical management of HIV-1 resistance.

Paredes R, Clotet B. Paredes R, et al. Antiviral Res. 2010 Jan;85(1):245-65. doi: 10.1016/j.antiviral.2009.09.015. Epub 2009 Oct 4. Antiviral Res. 2010. PMID: 19808056 Review.

10

Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

Buzón MJ, Codoñer FM, Frost SD, Pou C, Puertas MC, Massanella M, Dalmau J, Llibre JM, Stevenson M, Blanco J, Clotet B, Paredes R, Martinez-Picado J. Buzón MJ, et al. Among authors: paredes r. PLoS Pathog. 2011 Oct;7(10):e1002314. doi: 10.1371/journal.ppat.1002314. Epub 2011 Oct 27. PLoS Pathog. 2011. PMID: 22046128 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

719 results

Search Page